Review
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2023; 29(31): 4706-4735
Published online Aug 21, 2023. doi: 10.3748/wjg.v29.i31.4706
Dysregulated microRNAs as a biomarker for diagnosis and prognosis of hepatitis B virus-associated hepatocellular carcinoma
Ming-He Zhang, Yu-Feng Yuan, Li-Juan Liu, Yu-Xin Wei, Wan-Yue Yin, Lan-Zhuo-Yin Zheng, Ying-Ying Tang, Zhao Lv, Fan Zhu
Ming-He Zhang, Yu-Feng Yuan, Department of Hepatobiliary & Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
Ming-He Zhang, Li-Juan Liu, Yu-Xin Wei, Wan-Yue Yin, Lan-Zhuo-Yin Zheng, Ying-Ying Tang, Zhao Lv, Fan Zhu, State Key Laboratory of Virology, Department of Medical Microbiology, School of Basic Medical Sciences, Wuhan University, Wuhan 430071, Hubei Province, China
Yu-Xin Wei, Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China
Lan-Zhuo-Yin Zheng, Department of Cardiology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
Ying-Ying Tang, Department of Neurology, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China
Fan Zhu, Hubei Province Key Laboratory of Allergy & Immunology, Wuhan University, Wuhan 430071, Hubei Province, China
Author contributions: Zhang MH gathered the pertinent literature, drafted the initial manuscript, and conceptualized the tables and figures; Yuan YF, Liu LJ, Wei YX, Yin WY, Zheng LZY, Tang YY, Lv Z, and Zhu F conceptualized the text's structure and revised it for significant intellectual content; all authors have viewed and approved the final manuscript version.
Supported by the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University, No. ZNLH201902.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fan Zhu, PhD, Professor, State Key Laboratory of Virology, Department of Medical Microbiology, School of Basic Medical Sciences, Wuhan University, No. 185 Donghu Road, Wuhan 430071, Hubei Province, China. fanzhu@whu.edu.cn
Received: March 28, 2023
Peer-review started: March 28, 2023
First decision: June 17, 2023
Revised: June 29, 2023
Accepted: August 1, 2023
Article in press: August 1, 2023
Published online: August 21, 2023
Processing time: 142 Days and 22.3 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Hepatitis B virus (HBV) infection is one of the predominant risk factors for developing HCC. Early diagnosis and prognosis prediction are pivotal for patients with HBV-associated HCC (HBV-HCC) in their clinical management. MicroRNAs (miRNAs), a subset of non-coding RNAs, play an essential role in human diseases including HBV-HCC. Here, we summarize the role of miRNAs in the diagnosis and prognosis prediction of patients with HBV-HCC. Furthermore, we discuss the underlying mechanism by which HBV dysregulates miRNAs, and the potential role of dysregulated miRNAs in promoting hepatocarcinogenesis, laying the foundation for applying potential therapeutic targets.